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Summary  
 
Schizophrenia affects 1% of the world’s population, but its cause remains obscure. Numerous theories
have been proposed regarding the cause of schizophrenia, ranging from developmental or neurodegenerative
processes or neurotransmitter abnormalities to infectious or autoimmune processes. In this review, findings
suggestive of immune dysregulation and reactivity to self in patients with schizophrenia are examined with reference
to criteria for defining whether or not a human disease is autoimmune in origin. Associations with other autoimmune
diseases and particular MHC haplotypes, increased serum levels of autoantibodies, and 
 
in vivo
 
 and 
 
in vitro
 
replication of some of the functional and ultrastructural abnormalities of schizophrenia by transfer of autoantibodies
from the sera of patients with schizophrenia suggest that, in some patients at least, autoimmune mechanisms could
play a role in the development of disease. Recent findings regarding specific autoimmune responses directed against
neurotransmitter receptors in the brain in patients with schizophrenia will also be reviewed.
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Introduction
 
Schizophrenia is a severe, disabling psychiatric disorder that
affects approximately 1% of the world’s population. Written
accounts of the symptoms that are now associated with
schizophrenia can be found throughout history. However, it
was not until the late 19th century that a formal diagnosis of a
distinct form of psychosis separate from those caused by
diseases such as syphilis was formed. Termed dementia
praecox (dementia of the young) by Emil Kraepelin, the
disorder was differentiated from manic-depressive disorder
by its classic poor long-term prognosis compared to the
relatively non-deteriorating course of manic-depressive ill-
ness.
 
1
 
 In 1911 Eugene Bleuler proposed the term schizo-
phrenia (splitting of the mind) for the disorder that was
characterized by abnormalities in thought processes, percep-
tion and content of thought and by withdrawal of interest in
other people, rather than by dementia.
 
2
 
The exact cause of schizophrenia is not known, and patients
are diagnosed based on the presence of several distinct
symptoms and the absence of any detectable organic cause for
these features. The characteristic symptoms of schizophrenia
can vary in both type and severity, and many attempts have
been made to classify ‘schizophrenic subtypes’ according to
the predominant symptoms. The most general classification
currently used is of positive and negative symptoms. Positive
symptoms occur in most people with schizophrenia and are
generally associated with a good response to classical anti-
psychotic drugs; they are characterized by an excess of normal
function and include hallucinations, delusions and disorgan-
ized thoughts. Negative symptoms such as loss of function,
impaired concentration, diminished social engagement, dimin-
ished emotional expression and anhedonia are associated with
a poor response to antipsychotic treatment and predominate in
approximately one third of all people with schizophrenia.
Disorganized symptoms of formal thought disorder and dis-
organized behaviour may be considered to comprise a third
group of symptoms.
 
3
 
Several aetiological theories have been proposed for
schizophrenia, including developmental
 
4
 
 or neurodegenerative
processes,
 
5
 
 neurotransmitter abnormalities,
 
6–8
 
 viral infection
 
9,10
 
and immune dysfunction or autoimmune mechanisms.
 
11–22
 
 In
addition, there is substantial evidence for a genetic predis-
position to schizophrenia.
 
23,24
 
 However, none of the current
aetiological theories can fully explain the varied presentations
observed in different patients. The mechanism of action of
antipsychotic drugs suggests, however, that schizophrenia
results from either blocking or over stimulation of normal
neurotransmission (Fig. 1). With recent advances in technol-
ogy and an increased understanding of the immune system,
autoimmune theories of schizophrenia have once again become
a major focus of research. This paper will review the literature
regarding altered immunological findings in schizophrenia
and will examine whether the criteria for defining schizo-
phrenia as an autoimmune disease are met.
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Immune dysregulation in schizophrenia
 
The question of whether some or all cases of schizophrenia
have an immune or autoimmune aetiology has been asked
now for nearly 100 years. Many general immune abnormalities
have been reported over this time. These include morpholog-
ical changes in lymphocytes, altered levels of CD4
 
+
 
CD45RA
 
+
 
T cells, CD8
 
+
 
 T cells, CD5
 
+
 
 B cells and 
 
γδ
 
 T cells, increased
or decreased levels of 
 
γ
 
-globulin in serum, increased levels of
circulating cytokines, particularly IL-2, IFN-
 
γ
 
 and IL-6, and
increased levels of antiviral antibodies. These aspects of
altered immune reactivity in schizophrenia have recently been
thoroughly reviewed,
 
25
 
 and are therefore not discussed in
detail here.
Despite the numerous reports of immune abnormalities in
schizophrenia, the hypothesis that these abnormalities are
related to the pathogenesis of the disease continues to be
viewed with much scepticism. This has largely been because
many studies have failed to control for extraneous factors
such as antipsychotic medication, the duration and current
clinical status of schizophrenia, nutritional status, substance
abuse or concurrent illness, any of which may alter immune
responses and lead to the apparent abnormalities. Recent
studies, however, suggest that a functional adaptive immune
system is necessary for cognitive function because mice
deprived of mature T cells have been found to manifest
cognitive deficits and behavioural abnormalities that can be
ameliorated by T-cell restoration.
 
26
 
Some of the altered immunological factors identified in
schizophrenia could promote the development or maintenance
of autoimmunity. For example, increased levels of IL-6 have
been found consistently in the sera of people with schizo-
phrenia.
 
27–32
 
 Interleukin-6 is released from various cell types
in the blood and, as one of its main functions is to activate B
cells to synthesize antibodies,
 
33
 
 elevated serum IL-6 levels
could result in an increased humoral immune response. It has
also been suggested that IL-6 may mediate the exacerbation
of autoimmune disorders in the central nervous system (CNS)
by supporting local IgG synthesis in the CNS
 
34
 
 and promoting
disturbances of the blood–brain barrier (BBB).
 
35
 
Furthermore, in a study from Korea, the genotype and allele
distribution of an A/G single nucleotide polymorphism (SNP)
at position 49 in exon 1 of the cytotoxic T lymphocyte-
associated protein 4 (CTLA-4) gene, which has previously
been proposed to regulate CTLA-4 function, was found to be
significantly different between patients with schizophrenia and
healthy controls.
 
36
 
 CTLA-4 is a CD28 homologue that plays
an important role in the negative regulation of T-cell responses;
its transient expression on the surface of activated T cells
antagonizes the activating signals and terminates the T-cell
response. Differences between patients and controls at this SNP
have also been described in a variety of autoimmune diseases
including systemic lupus erythematosus (SLE), multiple
sclerosis, Hashimoto’s thyroiditis, Graves’ disease and type 1
diabetes mellitus.
 
37,38
 
 Thus, such polymorphisms might increase
susceptibility to development of immune reactivity to self.
 
An autoimmune hypothesis of schizophrenia
 
The argument in favour of an autoimmune basis for schizo-
phrenia was popularized by Burch in the early 1960s.
 
39
 
 After
analysing the age-specific and sex-specific incidence rates
and prevalence of several conditions presumed to be auto-
immune in origin, he concluded that schizophrenia also had
an autoimmune basis because the age of onset, sex differences
and relapsing clinical course matched well with diseases such
as rheumatoid arthritis. Many subsequent studies have noted
similarities between schizophrenia and other autoimmune
diseases. However, this alone is not sufficient evidence for
establishing schizophrenia as an autoimmune disease. In the
1950s, Witebsky and colleagues
 
40
 
 proposed criteria that could
be used to determine whether a disease is actually auto-
immune in origin, and these criteria were more recently
refined by Rose and Bona.
 
41
 
 The criteria propose several
levels of evidence: direct evidence (i.e. transmissibility by
lymphoid cells or antibody of the characteristic lesions of the
disease from human to human or human to animal, or repro-
duction of the functional defects characteristic of the disease
 
in vitro
 
), indirect evidence (i.e. reproduction of the autoimmune
disease in experimental animals or isolation of autoantibodies
 
Figure 1
 
Neurotransmission. The nerve impulse (action poten-
tial) travels down the presynaptic axon towards the synapse,
where it activates voltage-gated calcium channels leading to
calcium influx, which triggers the simultaneous release of neuro-
transmitter molecules from many synaptic vesicles by fusing the
membranes of the vesicles to that of the nerve terminal. The
neurotransmitter molecules are expelled into, and diffuse across,
the synaptic cleft, bind briefly to receptors on the postsynaptic
neurone to activate them, causing physiological responses that
may be excitatory or inhibitory depending on the receptor. The
neurotransmitter molecules are then either quickly pumped back
into the presynaptic nerve terminal via transporters (e.g. dopamine,
GABA), are destroyed by enzymes near the receptors (e.g. break-
down of acetylcholine by cholinesterase) or diffuse into the
surrounding area. Researchers believe that schizophrenia results
from blocking or over stimulation of normal neurotransmission.
Known sites of attack by autoantibodies in other diseases of the
nervous system include the voltage-gated calcium channels (in
Lambert–Eaton myasthenic syndrome) and the neurotransmitter
receptors (in myasthenia gravis and Rasmussen’s encephalitis).
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or autoreactive T cells from the target organ), and circumstan-
tial evidence (i.e. the presence of markers that are descriptive
of autoimmune disease). The evidence provided in the schizo-
phrenia literature for each level of the criteria is summarized
below.
 
Circumstantial evidence of autoimmunity
 
Several features are common to many autoimmune diseases,
namely, association with other autoimmune diseases in the
same individual or the same family, the presence of immune
cells in the affected organ, association with particular MHC
haplotypes, high serum levels of autoantibodies, deposition of
antigen–antibody complexes in the affected organ and
improvement of disease symptoms with immunosuppression.
 
Association with other autoimmune diseases
 
Epidemiological studies have shown that relatives of people
with schizophrenia have an increased risk of developing
several other autoimmune diseases, particularly type 1 diabetes
mellitus and thyrotoxicosis.
 
42,43
 
 In patients with schizophre-
nia, there is a strong negative correlation with rheumatoid
arthritis.
 
44
 
 Patients with coexistent schizophrenia and other
autoimmune diseases have been reported in individual case
studies, but no large-scale epidemiological studies have been
done that specifically address whether patients with schizo-
phrenia have a higher incidence of other autoimmune diseases
than do the general population. One study, however, found
that the prevalence of antithyroid antibodies was almost
doubled in both male and female schizophrenic patients
compared to controls.
 
45
 
Systemic lupus erythematosus has an interesting associa-
tion with schizophrenia because it arises relatively frequently
in patients with schizophrenia, particularly as a result of
treatment with phenothiazine or dibenzodiazepine antipsychotic
agents.
 
46–48
 
 The reasons for development of drug-induced SLE
remain poorly understood, but it may indicate that some
patients with schizophrenia have an underlying susceptibility
to the development of autoimmunity. In addition, a number of
SLE patients develop a schizophrenia-like psychosis resulting
from cerebral lupus. This is discussed in more detail under
‘Indirect evidence’.
 
Presence of immune cells in the target organ
 
There is no overt inflammatory infiltrate of mononuclear cells
in the brains of the majority of patients with schizophrenia.
There are, however, reports of an increased frequency of
activated lymphocytes in the cerebrospinal fluid (CSF), the
fluid that bathes the brain and spinal cord, of patients with
acute schizophrenia.
 
49,50
 
 Only one study has investigated
whether immunoglobulin can be detected in the brains of
people with schizophrenia: Heath and Krupp
 
51
 
 found that a
fluorescein-tagged antihuman antibody labelled the nuclei of
some neural cells in the brain tissues from 12 of 14 patients
with schizophrenia, but not in the tissues from any of 19 non-
schizophrenic controls.
 
Association with particular MHC haplotypes
 
Several MHC associations have been reported for schizophrenia.
Because of the negative correlation between schizophrenia
and rheumatoid arthritis, a disease that exhibits genetic asso-
ciation with the HLA-DRB1*04 gene, several studies have
investigated the frequency of carriage of DRB1*04 in patients
with schizophrenia and found that only half the expected
number of schizophrenic patients carried this gene compared
with controls.
 
52
 
 In addition, preferential non-transmission of
DRB1*04 alleles from heterozygous parents to their schizo-
phrenic offspring also occurs.
 
53
 
 One study has linked certain
schizophrenia subtypes with the carriage of DQB1*0602,
 
54
 
but this association has not been found by other researchers,
 
52
 
and in African American schizophrenic patients there appears
to be a negative correlation with this allele.
 
55
 
 In Japanese
populations, a higher incidence of DRB1*0101 is found
compared to healthy controls.
 
56
 
 Recently, a chip-based mass
spectrometry analysis for SNP within a 25 Mb region on
human chromosome 6p21 (which covers the MHC) found a
significant increase in schizophrenia, compared to other dis-
eases and healthy controls, in the frequency of a SNP in HLA-
DOA, a molecule found inside the cell that modulates MHC
class II-restricted antigen presentation by interacting with
HLA-DM, and a significant decrease in the frequency of a
SNP in HLA-DRB1.
 
57
 
High serum levels of autoantibodies
 
As early as the 1930s, circulating antibodies specific for
antigens found in post-mortem brains from people with
schizophrenia were reported to occur in sera from people with
schizophrenia.
 
58
 
 However, around this time the popularity of
psychoanalytical psychiatry was growing substantially and
that, coupled with the limited knowledge of the immune
system at the time, meant that investigations into specific
immune responses in schizophrenia were largely forgotten
until the 1960s, by which time the concept of autoimmunity
had developed significantly.
In the early 1960s several investigators described a variety
of antibrain antibodies in the sera of patients with schizophre-
nia.
 
51,59,60
 
 In an attempt to replicate these results many studies
have been conducted searching for the presence of autoanti-
bodies in the sera of people with schizophrenia, but consist-
ency in the findings between different research groups has not
been high (Table 1). Several groups have reported the increased
occurrence of autoantibodies in people with schizophrenia,
when compared to controls, against the brain or specific areas
of the brain (including the cerebrum,
 
61
 
 septum
 
62
 
 and amygdala,
frontal cortex, cingulate gyrus and septal area
 
63
 
), or against
brain constituents such as gangliosides.
 
64
 
 However, other
research groups have found no significant differences
between people with schizophrenia and controls in the levels
of antibodies directed against brain,
 
18
 
 brain septal regions,
 
65
 
hippocampus,
 
66
 
 brain lipids
 
67
 
 or gangliosides.
 
68
 
Antibodies against several neurotransmitter receptors have
also been investigated in schizophrenia, with numerous
research groups proposing that the presence of such autoanti-
bodies could block or stimulate neurotransmitter receptors
and could be the cause of the diverse symptoms observed in
patients with schizophrenia.
 
22,69–71
 
 Several groups have reported
significantly higher levels of antibodies to cerebral M
 
1
 
 cho-
linergic muscarinic receptors,
 
70,72,73
 
 nicotinic acetylcholine
receptors,
 
74
 
 dopamine D
 
2
 
 receptors,
 
73,75
 
 astrocyte M
 
1
 
 and M
 
2
 
muscarinic cholinergic receptors,
 
72
 
 mu-opioid and serotonin
(5-HT
 
1A
 
) receptors
 
73
 
 in sera from people with schizophrenia
when compared to sera from healthy controls. Despite the
relatively small numbers of patients in most of these studies
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and a lack of disease specificity for some of these antibodies
to schizophrenia alone (one group found antibodies to several
neurotransmitter receptors in serum samples from people with
psychiatric diseases other than schizophrenia
 
73
 
), the results
are nevertheless suggestive of an autoimmune response
directed against neurotransmitter receptors in at least some
patients with schizophrenia. Recent direct evidence of a
functional role for some of the neurotransmitter receptor
antibodies will be discussed below.
A large number of studies have investigated organ non-
specific autoantibodies, such as those against DNA, heat
shock proteins and the nucleus, because these are often
increased in patients with an autoimmune disease even if
organ-specific autoantibodies are not. A significantly higher
frequency of circulating antinuclear antibodies in people with
schizophrenia compared to controls has been found in a
number of studies,
 
76–78
 
 whereas others
 
79,80
 
 have found no signif-
icant increase in antinuclear antibodies in never-medicated
people with schizophrenia compared to controls. Autoanti-
bodies to both single and double-stranded DNA have also
been found to be significantly more common in people with
schizophrenia compared to controls by one group
 
77
 
 and not
present at all by another research group.
 
78
 
Several possible reasons could account for the discrepan-
cies in findings from different research groups. The hetero-
geneity of the disease and the diagnostic criteria used to
classify patients could influence results, in that patients with
drastically different presentations (that could be indicative of
different disease processes or causes) are being compared
against one another. The medication status of patients could
also influence results, with patients who are neuroleptic naïve
being compared with patients who are merely currently
unmedicated but who have had previous exposure to anti-
psychotic medication. The techniques used by different research
groups have also varied markedly over the 40-year timespan
in which the tests have been done, with some studies using
much more sensitive techniques than others.
 
Deposition of antigen–antibody complexes in the affected 
organ
 
It has been proposed that schizophrenia may be caused by a
covert immune complex-driven basal lamina disease of the
choroid plexus.
 
81
 
 This proposal was largely based on findings
from patients with SLE and associated schizophreniform
psychoses, in which immune complexes are deposited in the
choroid plexus. In schizophrenia itself, however, no studies
have investigated whether or not such immune complex
deposition occurs. One research group has reported that
concentrations of circulating immune complexes are elevated
in the blood of many patients with schizophrenia compared
to chronic alcoholics;
 
82
 
 however, another group found no
increased incidence of circulating immune complexes.
 
12
 
Improvement of disease symptoms with immunosuppression
 
Despite the popularity of the autoimmune hypothesis for
schizophrenia, few studies have reported results of trials of
immunosuppressive agents in schizophrenia. Plasma exchange
was not found to affect the course of schizophrenia in one
small trial of 10 patients;
 
83
 
 however, it has been noted that
most autoimmune diseases (with the exception of acute
Guillain–Barré syndrome) appear to require the combined
use of immunosuppressive drugs and/or lymphocytapheresis
for successful outcomes with plasmapheresis.
 
84
 
 Levine and
colleagues
 
85
 
 showed that short-term treatment with azathio-
prine improved the psychiatric symptomatology in a sub-
group of patients with schizophrenia. Few other studies have
set out to test well-defined immunosuppressive agents in
schizophrenia. However, it is known that some of the anti-
psychotic drugs such as haloperidol and clozapine are highly
immunosuppressive.
 
86
 
 If autoimmune responses are playing a
role in the development of schizophrenia, then treatment with
some of the common antipsychotic drugs may act synergisti-
cally as direct antagonists of brain neurotransmitter receptors
and also as inhibitors of autoimmune responses, thus leading
to amelioration of psychotic behaviour.
 
Indirect evidence of autoimmunity
 
In general, indirect evidence of autoimmunity includes such
observations as the induction of autoimmunity in an animal
model or the finding of autoimmune cells or antibodies in the
target organ. No appropriate experiments to investigate these
aspects of autoimmunity have been carried out for schizo-
phrenia. Probably the best indirect evidence for an autoimmune
basis for schizophrenia comes from studies examining SLE, a
known autoimmune disease characterized by the presence of
autoantibodies against double-stranded DNA. Between 14%
and 75% of patients with SLE are estimated to experience
neuropsychiatric symptoms, including mood and behavioural
disturbances and psychotic symptoms.
 
87,88
 
 Recently it has
been shown that a subset of anti-DNA antibodies can cross-
react with the NR2 subunit of the N-methyl-D-aspartate
(NMDA) glutamate receptor.
 
89
 
 If the psychotic symptoms in
SLE patients are the result of anti-DNA antibodies cross-
reacting with the glutamate receptor, then it is possible that
the psychotic symptoms in some schizophrenic patients could
be caused by similar reactions of antibodies with neurotrans-
mitter receptors.
 
Table 1
 
Autoantibodies detected in people with schizophrenia
compared with controls
Autoantibody to Finding Reference
Brain Significantly higher
 
51,63,64,112,113
 
None detected
 
18,114,115
 
No difference
 
116–118
 
Brain septal region No difference
 
65
 
Significantly higher
 
62
 
Brain lipids No difference
 
67
 
Cerebellum Significantly higher
 
61
 
Gangliosides No difference
 
68
 
Hippocampus No difference
 
66
 
Cell nuclei Significantly higher
 
76,78
 
No difference
 
79,80
 
Present in sera
 
119
 
Lymphocyte nuclei Significantly higher
 
120
 
DNA Significantly higher
 
77
 
None detected
 
78
 
Anticardiolipin Significantly higher
 
121
 
Heat shock proteins Significantly higher
 
122,123
 
Gastric parietal cells Higher frequency
 
79
 
Present in sera
 
119
 
Platelets Significantly higher
 
124
 
Neurotransmitter receptors Significantly higher
 
70,72–75
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Direct evidence of autoimmunity
 
The most direct evidence for an autoimmune aetiology of a
disease is that direct transfer of T cells or antibody from a
diseased to a healthy individual can induce the characteristic
lesions of the disease. In the 1960s Heath 
 
et al.
 
59
 
 isolated a
protein that they termed ‘taraxein’ from the sera of actively
psychotic people with schizophrenia. Taraxein was later
identified as an immunoglobulin, but its specificity was not
determined. When administered intravenously into monkeys,
taraxein caused electroencephalographic (EEG) changes in
the monkeys similar to those observed in people with schizo-
phrenia. In addition, when taraxein was injected intravenously
into healthy human volunteers it resulted in similar EEG
changes and the induction of psychotic symptoms comparable
to those observed in the active psychosis stage of schizo-
phrenia. Later studies from the same group using antibodies
induced in rabbits with specificity for the septum pellucidum
of the brain showed that these antibodies could produce focal
EEG changes when injected into cats.
 
90
 
In an attempt to reproduce the results of Heath 
 
et al.
 
’s
studies, Bergen and colleagues
 
91
 
 used IgG purified from the
blood of acutely ill schizophrenic patients and injected it into
the CSF of rhesus monkeys. They found that 22% of sera
from patients with schizophrenia compared with 7% of sera
from healthy controls were able to induce EEG abnormalities
in the monkeys. The results obtained using IgG from patients
with schizophrenia were similar to the results recorded by
Heath 
 
et al.
 
; however, the previous work had reported that no
abnormalities occurred using sera from healthy controls.
Purified IgG from the blood of patients with schizophrenia
has also been injected intracisternally into the CSF of rats,
and subsequent electron microscopic and biochemical studies
used to investigate changes in the brains of the rats. It was
found that ultrastructural abnormalities of the sensorimotor
cortex and activation of lipid peroxidation occurred; these
changes were similar to the alterations that can be detected in
the brains of patients with schizophrenia.
 
92
 
These early experiments support the hypothesis that auto-
antibodies from some patients with schizophrenia have the
potential to transmit disease from one individual to another.
However, they provide little explanation of how such an
effect might occur. Recently, it has been shown that autoanti-
bodies purified from the blood of patients with schizophrenia
that are specific for the M1 muscarinic acetylcholine receptor
(mAChR), one of several neurotransmitter receptors impli-
cated in schizophrenia, can exert functionally relevant effects
in 
 
in vitro
 
 assays.
 
72
 
 These antibodies have been shown to inhibit
the binding of natural ligands to the receptors and to display
agonistic-like activity leading to M1 mAChR activation.
 
Does schizophrenia in some patients result from an 
autoantibody-mediated autoimmune disease?
 
The findings presented in the preceding section give many
hints that, in some patients at least, autoantibodies could play
a role in the development of schizophrenia. The finding of
neurotransmitter-receptor-specific antibodies that appear to
have functional properties
 
72
 
 represents a substantial step forward
in our understanding of how such autoimmune responses
might lead to schizophrenia; however, the mechanisms are
not entirely unexpected. Functional autoantibodies that inhibit
or stimulate receptor-mediated neurotransmission have been
reported for several different diseases. For example, IgG in
the sera of children with congenital heart block can bind and
activate 
 
β
 
-adrenoceptors and mAChR receptors of the neo-
natal heart.
 
93
 
 Similarly in patients with Chagas’ disease, a
cardiomyopathy induced by infection with 
 
Trypanosoma
cruzi
 
, antibodies specific for a ribosomal protein of 
 
T. cruzi
 
cross-react with 
 
β
 
1 adrenergic receptors of the human heart,
activating the receptor excessively and leading to receptor
desensitization and internalization.
 
94
 
 In addition, functional
autoantibodies against M3 mAChR can be found in patients
with scleroderma and Sjögren’s syndrome.
 
95
 
 Neurotransmitter-
receptor-specific autoantibodies have been found in patients
with several autoimmune diseases affecting the peripheral
nervous system and are believed to be responsible for the
symptoms of those diseases. In some cases, the autoanti-
bodies bind to the neurotransmitter receptor and prevent the
normal ligand from binding, resulting in a reduction in the
number of functional neurotransmitter receptors by increasing
the receptor internalization. One example of this type of
antibody-mediated disruption of neurotransmission is observed
in myasthenia gravis in which autoantibodies bind to post-
synaptic nicotinic acetylcholine receptors in the neuromuscular
junction, with a resultant increase in internalization of the
neurotransmitter receptors and a decrease in the number of
functional receptors. In CNS disorders, several autoantibodies
against known neurotransmitter autoantigens have been
reported that are pathogenic either 
 
in vitro
 
 or 
 
in vivo
 
 (reviewed
recently by Lang et al.96). For example, in Rasmussen’s
encephalitis, a rare cause of epilepsy, autoantibodies bind
selectively to ionotropic glutamate receptors and destroy
neuronal cells via activation of the complement pathway.97
Other structures in and around the synaptic junction could
also be targeted by autoantibodies, leading to functional effects
similar to those observed with the neurotransmitter-receptor-
specific autoantibodies (Fig. 1). For example, in Lambert–
Eaton myasthenic syndrome, binding of antibodies specific for
L-, N- or P/Q-type voltage-gated calcium channels (VGCC)
leads to morphological changes (cross-linking) in the active
zone particles at the nerve terminals and inhibits the release of
the neurotransmitter from the nerve terminals. Synaptotagmin,
one of the functionally VGCC-associated synaptic proteins, is
also targeted by autoantibodies in this syndrome.98,99
Could autoantibody-mediated damage at the synapse in
schizophrenia cause a similar clinical phenotype to that which
would be caused by some of the other putative pathogenic
processes in schizophrenia, such as genetic mutations or neuro-
developmental abnormalities? This is not yet known for
schizophrenia; however, it is known that such widely variant
pathological processes can result in a very similar end-stage
clinical phenotype. For example, a similar clinical phenotype
is observed in myasthenia gravis (mediated by anti-acetylcholine
receptor antibodies) and in several different congenital
myasthenic syndromes caused by mutations in genes encoding
the acetylcholine receptor ∈ chain or the acetylcholinesterase
collagen anchor. Thus, while some cases of schizophrenia
may result from genetic or neurodevelopmental disruption to
one or more components of the synapse, it is possible that, in
other cases, autoantibodies directed against the same compo-
nents could lead to very similar clinical manifestations.
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How do the autoantibodies get into the nervous system?
One difficulty in accepting the idea of an autoantibody-
mediated disease of the CNS is the widely held belief that the
BBB limits the access of circulating antibody to the normal
nervous system; however, at least one antibody has been
reported to cross the intact BBB.100 In addition, there is
evidence that activated B cells can cross the intact BBB and
enter the CNS, clonally expand and produce antibody.101,102
However, for most circulating antibodies against the brain to
play a role in disease, the BBB probably needs to be impaired
in some way. For example, in multiple sclerosis, an auto-
immune CNS disorder, damage to the BBB allows antibodies
and complement access to the brain. In schizophrenia, how-
ever, there is no clear evidence of T-cell infiltration of the
CNS or disruption of the BBB. One study has suggested that
there may be an underlying inflammatory process occurring
in the brains of people with schizophrenia based on the
presence of fibrin degradation products in the CNS,103 whereas
another group have found no evidence of CNS inflammation
based on two indicators of inflammation, neopterin and
macrophage inflammatory protein-1α (MIP-1α).104 It has also
been suggested that increased levels of soluble circulating
intercellular adhesion molecule-1 (ICAM-1) in some people
with schizophrenia are indicative of damage to, or increased
permeability of, the BBB105,106 and that both typical and
atypical antipsychotic drugs may induce alterations in the
BBB.107 Several groups have used the ratio of CSF/serum
albumin as a measure of the permeability of the BBB and
have found increased permeability in 15–30% of people with
schizophrenia.105,108–111
Thus, several possibilities exist: many patients with schizo-
phrenia may produce autoantibodies against neurotransmitters
or other brain structures that have the potential to be function-
ally relevant, but these antibodies may play a role in disease
pathogenesis only in those patients whose BBB is impaired or
who produce such antibodies locally in the CNS. Alternatively,
non-immune-mediated damage to the CNS in schizophrenia
may allow the release of autoantigens and the production of
autoantibodies, which may contribute to the symptoms of the
disease.
Conclusions
Schizophrenia is a devastating mental illness, the symptoms
of which affect the normal functioning of an individual by
causing a loss of contact with reality and by disturbing the
capacity for work and social interactions. The exact cause of
schizophrenia remains undetermined, although the clinical
symptoms and signs appear to result from either blocking or
over stimulation of normal neurotransmission. There is a
large volume of circumstantial evidence for an autoimmune
aetiology of at least some cases of schizophrenia. This evidence
includes the occurrence of other autoimmune diseases in the
relatives of people with schizophrenia, the association of
schizophrenia with particular HLA haplotypes and the pres-
ence of circulating autoantibodies. Because neurotrans-
mission is abnormal in schizophrenia, the finding of increased
levels of antibodies specific for several neurotransmitter
receptors and the demonstration that such antibodies can exert
functional effects in vitro constitute compelling evidence in
support of the hypothesis that autoantibodies may play a role
in the development of schizophrenia.
Further research is warranted to confirm the presence of
autoantibodies in people with schizophrenia and to ascertain
the targets of an antibody-mediated autoimmune response. If
autoantibodies directed against neurotransmitter receptors play
a functional role, as suggested by current evidence, then more
effective treatments based on the specific receptor systems
targeted by antibodies could be investigated, as could new
strategies for immunotherapeutic intervention in schizophrenia.
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